Antifungal Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global antifungal drugs market size reached US$ 14.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 18.0 Billion by 2028, exhibiting a growth rate (CAGR) of 3.6% during 2022-2028.
Antifungal drugs, or antimycotic drugs, refer to the pharmaceutical medicines used for the treatment of fungal infections on skin, hair and nails. Some of the commonly used antifungal drugs include polyenes, azoles and allylamines. They specifically neutralize fungal agents and dermatophytes, such as candida and tapeworms, and aid in the treatment of athlete’s foot, ringworm, aspergillosis, candidiasis and fungal meningitis. These drugs are commonly available in over the counter (OTC) capsule, gel, liquid and pill variants or intravenous solutions that are injected directly into the bloodstream to minimize and prevent fungal infection.
Antifungal Drugs Market Trends:
The increasing prevalence of fungal and nosocomial infections is one of the key factors creating a positive outlook for the market growth. Antifungal drugs are effective against both systemic and superficial infections that are acquired from exposure to contaminated surfaces in hospitals or humid conditions. Moreover, the convenient availability of OTC drugs in both urban and rural areas is providing a thrust to the market growth. With the rising health consciousness among the masses, consumers are increasingly opting for OTC therapeutics to timely treat minor infections. Additionally, various product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, are acting as other growth-inducing factors. Pharmaceutical manufacturers are also investing extensively in the research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets and injections with enhanced efficacy. Other factors, including significant growth in the pharmaceutical industry, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antifungal drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class and indication.
Breakup by Drug Class:
Azoles
Voriconazole (Vfend)
Posaconazole (Noxafil)
Clotrimazole (Canesten)
Isavuconazole (CRESEMBA)
Others
Echinocandins
Caspofungin (Cancidas)
Micafungin (Mycamine/ Funguard)
Others
Polyenes
Amphotericin (AmBisome)
Others
Allylamines
Terbinafine (Lamisil)
Others
Others
Breakup by Indication:
Dermatophytosis
Aspergillosis
Candidiasis
Invasive Candidiasis
Vulvovaginal Candidiasis (VVC)
Mouth/Throat/Esophageal Candidiasis
Others
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc., Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Scynexis Inc.
Key Questions Answered in This Report
1. What was the size of the global antifungal drugs market in 2022?
2. What is the expected growth rate of the global antifungal drugs market during 2023-2028?
3. What has been the impact of COVID-19 on the global antifungal drugs market?
4. What are the key factors driving the global antifungal drugs market?
5. What is the breakup of the global antifungal drugs market based on the drug class?
6. What is the breakup of the global antifungal drugs market based on the indication?
7. What are the key regions in the global antifungal drugs market?
8. Who are the key players/companies in the global antifungal drugs market?
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Antifungal Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Drug Class
- 6.1 Azoles
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Voriconazole (Vfend)
- 6.1.2.2 Posaconazole (Noxafil)
- 6.1.2.3 Clotrimazole (Canesten)
- 6.1.2.4 Isavuconazole (CRESEMBA)
- 6.1.2.5 Others
- 6.1.3 Market Forecast
- 6.2 Echinocandins
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Caspofungin (Cancidas)
- 6.2.2.2 Micafungin (Mycamine/ Funguard)
- 6.2.2.3 Others
- 6.2.3 Market Forecast
- 6.3 Polyenes
- 6.3.1 Market Trends
- 6.3.2 Key Segments
- 6.3.2.1 Amphotericin (AmBisome)
- 6.3.2.2 Others
- 6.3.3 Market Forecast
- 6.4 Allylamines
- 6.4.1 Market Trends
- 6.4.2 Key Segments
- 6.4.2.1 Terbinafine (Lamisil)
- 6.4.2.2 Others
- 6.4.3 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 7 Market Breakup by Indication
- 7.1 Dermatophytosis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Aspergillosis
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Candidiasis
- 7.3.1 Market Trends
- 7.3.2 Key Segments
- 7.3.2.1 Invasive Candidiasis
- 7.3.2.2 Vulvovaginal Candidiasis (VVC)
- 7.3.2.3 Mouth/Throat/Esophageal Candidiasis
- 7.3.2.4 Others
- 7.3.3 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
- 9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
- 10 Value Chain Analysis
- 11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
- 12 Price Analysis
- 13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Arcadia Consumer Healthcare Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.3 Astellas Pharma Inc.
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Bayer AG
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 GlaxoSmithKline Plc
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.6 Merck & Co. Inc.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Merck KGaA
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Novartis AG
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Pfizer Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Sanofi S.A.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Scynexis Inc.
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.11.3 Financials
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook